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Abstract
Glaucoma is an optic nerve neuropathy of undetermined cause. Although many mechanisms are thought 
to be involved in the development and progression of the disease, only an increased intraocular pressure 
has been established as a clinically significant modifiable risk factor. Nevertheless, up to 40% of patients 
develop glaucoma without evidence of increased intraocular pressure. 
Ample evidence suggests that alterations in the control of arterial blood might negatively affect optic 
nerve function. However, evidence-based guidelines on the management of arterial blood pressure in 
glaucoma patients are lacking.
Regrettably, intraocular pressure is generally not included as a secondary end-point in clinical trials 
on arterial hypertension. Considering the relative simplicity of intraocular pressure measurements 
and large number of patients included in hypertension studies, the benefits of including intraocular 
pressure as a secondary end-point could be of a great value for improving care for glaucoma patients. 
Therefore, closer collaboration between cardiologists and ophthalmologists is needed. (Cardiol J 2019;  
26, 1: 8–12)
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Introduction
Glaucoma is a progressive optic nerve neu-
ropathy [1]. It is estimated that by 2040 at least 
112 million people will be diagnosed with glaucoma 
worldwide [2]. Increased intraocular pressure 
(IOP) is the only modifiable glaucoma risk factor 
which has been well established in clinical practice 
[1]. Pharmacotherapy, laser or surgical procedures 
are utilized to lower IOP and prevent deterioration 
of visual field defects [1]. However, up to 40% of 
patients develop glaucomatous neuropathy without 
any evidence of increased IOP [3]. This observation 
prompted research into alternative causes of optic 
nerve damage and abnormal level of arterial blood 
pressure (ABP) — both too low and too high, was 
proposed as a possible risk factor [4]. Nevertheless, 
ophthalmologists are still far from evidence-based 
management of ABP in glaucoma patients.
In contrast, cardiologists have well established 
preferred practice patterns on the management 
of hypertension [5]. The most recent update 
of these guidelines recommends systolic blood 
pressure (SBP) between 120 and 129 mmHg as 
a treatment goal in majority of high-risk patients 
[5]. Although the SPRINT study proved that a low 
ABP target significantly decreases mortality, and 
an intensified approach did not remain without side 
effects [6]. Acute kidney failure or syncope were 
reported by SPRINT investigators [6]. Interest-
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ingly, although a growing body of evidence shows 
a close link between glaucoma and ABP, eye-related 
end-points were not included in the study [4, 6]. 
Firstly, information could been have gained herein, 
on the impact of intensive lowering of ABP on the 
progression of optic neuropathy. Secondly, sub-
analyses could have revealed whether any antihy-
pertensive drugs should be preferred in patients 
with glaucoma. 
Considering that both hypertension and glau-
coma pose a major public health challenge, a closer 
collaboration between cardiology and ophthalmol-
ogy could bring cost-effective solutions to many 
unresolved questions and significantly improve 
patient care. 
Summarized here is the current state of knowl-
edge on the relationship between ABP and IOP. 
Furthermore, this study shows how landmark trials 
on hypertension could have benefitted patient care 
in ophthalmology. 
Blood pressure and glaucoma
High blood pressure and glaucoma
Large epidemiological studies show that ABP 
positively correlates with IOP. Beaver Dam Eye 
study reported an 0.21 mmHg increase in IOP 
for every 10 mmHg increase in SBP [7]. Similar 
correlation was shown by Egna-Neumarkt study 
— 0.24 mmHg IOP change per 10 mmHg increase 
in SBP [8].
The Blue Mountains Eye Study suggested 
that hypertension itself might be a risk factor for 
glaucoma, regardless of ABP and IOP correlation 
[9]. Additionally, data from the British General 
Practitioner Research Database and studies by 
Horwitz et al. suggest that patients with glaucoma 
are more often diagnosed with hypertension than 
the general population [10, 11].
However, the aforementioned observations 
lack a sound mechanistic explanation. On the one 
hand, it is hypothesized that an increased capillary 
pressure in the ciliary body translates into higher 
IOP [4]. On the other hand, fluctuations in IOP 
might depend on a common humoral background of 
IOP and ABP control [12]. As hypertension induces 
atherosclerosis and impairs vascular autoregula-
tion, some authors propose that it negatively affects 
blood supply to the optic nerve [13]. The latter 
hypothesis may explain observations of a higher 
prevalence of glaucoma in patients with systemic 
hypertension, irrespective of an ABP and IOP 
relationship [9]. 
Low blood pressure and glaucoma
Interestingly, some research contradicts stud-
ies claiming harmful effects of hypertension on 
the optic nerve. Recent analysis of the Maracaibo 
Aging Study showed that patients with hyperten-
sion have a lower risk of developing glaucoma 
[14]. What is more, it is hypothesized that a low 
ABP might accelerate progression of optic nerve 
neuropathy. Indeed, the Baltimore Eye Survey 
revealed that low office diastolic blood pressure 
(DBP) correlates with the prevalence of the optic 
neuropathy [15].
To further explain the relationship between 
low ABP and glaucoma progression, a parameter 
called ocular perfusion pressure (OPP) was in-
troduced [16]. OPP is defined as the difference 
between either SBP or DBP and IOP. It is believed 
that OPP better reflects vascular supply to the optic 
nerve head than an ABP value alone [17]. Although 
some argue that better correlation of OPP with the 
optic neuropathy reflects only an increased level 
of IOP, studies which adjusted the results for IOP 
seem to contradict these remarks [18, 19]. 
More detailed insight into a relationship be-
tween glaucoma and low ABP was provided along 
with the introduction of a 24 h ambulatory blood 
pressure measurement (ABPM). It has been shown 
that a nocturnal decrease of mean ABP of at least 
10 mmHg was a predictor of glaucoma progres-
sion [20]. These findings were also supported by 
a recent meta-analysis which showed that a dip-
ping pattern, defined as a nocturnal drop of ABP 
of more than 10%, correlates with glaucoma pro-
gression [21]. Nevertheless, it is of note that the 
abovementioned cut-off values for nocturnal ABP 
drop, are well within a normal range reported for 
a population [22]. 
In contrast, more recent reports, as Maracaibo 
Aging Study, suggest that it is not the physiological 
nocturnal hypotension that triggers optic nerve 
damage, but rather the non-physiological over-
dipping pattern of more than 20% [14]. Similar 
findings were presented by Pillunat et al. [23], who 
suggested that normotensive (but not hyperten-
sive) patients with an over-dipping pattern of ABP 
have an increased risk of glaucoma progression. 
Considering mechanisms of vascular auto-
regulation it might be puzzling to expect that even 
a physiological drop of ABP leads to the optic nerve 
ischemia. However, this chain of events reflects an 
impaired vascular regulation in glaucoma patients 
[24]. Under physiological conditions, in response 
to a drop of ABP, muscular arteries dilate and pro-
10 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
vide a sufficient nutritional supply to the target 
organs [25]. However, in the setting of an increased 
baseline vascular tone, as reported in glaucoma, 
autoregulation might be ineffective [24]. 
Antihypertensive therapy and glaucoma
Conflicting conclusions also come from studies 
focused on a link between glaucoma and systemic 
antihypertensive treatment. Thessaloniki Eye 
Study showed that treatment with antihyperten-
sive drugs, adjusted for a level of blood pressure, 
is associated with a more pronounced progression 
of glaucoma [26]. In contrast, Horwitz et al. [11] 
proves that although systemic hypertension is as-
sociated with an increased prevalence of glaucoma, 
onset of the optic nerve neuropathy is delayed by 
an intake of antihypertensive drugs. 
Furthermore, analyses focused on specific 
drug classes showed that treatment with calcium 
channel blockers positively correlates with the 
prevalence of glaucoma, whereas administration of 
beta-blockers might be protective [27, 28].
Finally, it has been also proposed that noc-
turnal (before sleep) administration of antihyper-
tensive medication affects optic nerve function to 
a greater extent in comparison to other times of 
the day [29]. 
Landmark hypertension clinical  
trials in the XXI century
According to the updated guidelines on sys-
temic hypertension [30], it is estimated that around 
40% of adults in the developed countries will 
be eligible for an ABP lowering treatment [30]. 
Furthermore, de Moraes et al. [31] reckons that 
at least 0.8% of people aged 40 and over will be 
diagnosed with both hypertension and glaucoma. 
Considering these estimates, it is of paramount 
importance to collect information on the relation-
ship between hypertension or antihypertensive 
treatment and glaucoma. Regrettably, none of the 
landmark studies on hypertension assessed IOP 
or optic nerve function as a secondary end-point. 
Herein, the present study reveals how these trials 
could have improved patient care in ophthalmology. 
SPRINT
The Systolic Blood Pressure Intervention Trial 
(SPRINT) was a double-blinded, controlled study 
which randomized high-risk hypertensive patients 
to intensive and standard treatment strategies 
with an SBP target of 120 mmHg and 140 mmHg, 
respectively [6]. It showed that lowering SBP 
below 120 mmHg might be of significant benefit 
to some hypertensive patients [6]. However, the 
study showed that although low ABP decreases 
mortality, it leads to some non-negligible systemic 
side effects and compels closer surveillance over 
this particular group of patients. The SPRINT 
trial reported that intensified treatment leads to 
an increased number of hypotensive episodes, 
syncope, acute kidney failure or electrolyte ab-
normalities [6]. Nevertheless, although there is 
a strong evidence that excessive ABP lowering has 
an effect on the optic nerve [20], no sub-analysis 
of the study addressed glaucoma progression as 
an adverse event of the SPRINT trial. Firstly, 
inclusion of eye related end-points in the SPRINT 
study with a follow-up of more than 3 years might 
have shown whether ABP values correlate with 
IOP. Secondly, sub-analyses could have revealed 
whether any group of antihypertensive drugs might 
be more favorable in terms of IOP in patients with 
hypertension. Finally, a large number of partici-
pants (more than 9000) and high co-occurrence of 
glaucoma and hypertension would permit insight 
into the effect of intensified hypertension treat-
ment on the progression of the optic neuropathy. 
Interestingly, although ABPM studies performed 
on SPRINT trial participants confirmed lower ABP 
in the intensive treatment group, they showed no 
effect of the treatment on a 24 h pattern of ABP 
[32]. This analysis could add some merit to the 
conflicting discussion whether low ABP, without 
a nocturnal over-dipping pattern, leads to the optic 
nerve damage.  
Renal denervation clinical trials
SYMPLICITY I, II and III renal denervation 
trials were aimed at patients with treatment resist-
ant hypertension defined as an ABP over 140/90 
mmHg despite treatment with at least 3 antihy-
pertensive drugs, including a diuretic [33–35]. 
Although these studies did not show any advantage 
of renal denervation over pharmacotherapy, they 
did prove patient safety for the procedure [33–35]. 
SPYRAL HTN-OFF, which followed, showed that 
renal denervation might offer a viable antihyper-
tensive management for patients who are not using 
ABP lowering medication [36]. The effectiveness 
of renal denervation is mechanistically tied to sym-
pathetic nervous system inhibition [33]. Consider-
ing that non-selective beta-blockers are utilized 
to lower IOP, it could be hypothesized that renal 
denervation could simultaneously decrease ABP 
and IOP [37], thus offering a viable alternative to 
pharmacotherapy in patients with both glaucoma 
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and hypertension. However, no sub-analyses on 
IOP were performed in multiple renal denervation 
studies performed worldwide. This analysis would 
help to assess the influence of the sympathetic 
nervous system on IOP regulation, and would be 
even more interesting considering that adrenaline 
drops, which were historically used to lower IOP 
[38], have now been replaced by beta-blockers. 
Perspectives — 24 hour ocular  
volume monitoring
A contact lens sensor (Triggerfish, Sensimed, 
Switzerland) dedicated for monitoring of 24 h 
ocular volume pattern, which correlates with in-
traocular pressure changes, has recently been 
approved as a medical device in Europe and the 
United States [39]. In the setting of research into 
ABP and IOP correlation, Triggerfish appears to 
be a far more robust tool compared to current gold 
standard of IOP measurement, i.e. Goldmann ap-
planation tonometry. Triggerfish records data for 
30 s every 5 min over 24 h [39]. Furthermore, it 
allows measurements in habitual body positions 
and is the only device that facilitates the record-
ing of IOP-related parameters during sleep [39]. 
Considering the aforementioned features and 
relative ease of fitting the sensor, its utilization 
could bring valuable information into discussion 
on the ABP and IOP relationship. However, its 
broad application is currently limited by the high 
cost, which is estimated at $700 USD per one 24 h 
measurement [40].
Conclusions
Although elevated IOP is currently considered 
as the only treatable risk factor of glaucoma, many 
patients develop the disease despite normal IOP [1]. 
Therefore, it is of paramount importance to identify 
and precisely describe other modifiable risk factors 
of optic nerve neuropathy.
A growing body of research shows that ABP 
has a strong effect on IOP or a risk of glaucoma. 
Nevertheless, analysis of current knowledge brings 
inconclusive results regarding an evidence-based 
approach to ABP management in glaucoma patients.
The present study propozes that inclusion of 
IOP and assessment of the optic nerve function as 
secondary end-points in clinical trials on hyperten-
sion might deliver valuable data for a multifactorial 
approach to glaucoma.
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